Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.Роберто Пили, Noah M. Hahn, Costantine Albany et al.|Journal of Clinical Oncology|2019Cited by 21